Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transcription elongation factor A N-terminal and central domain-containing protein (TCEANC) is a nuclear protein encoded by the TCEANC gene (UniProt Q8N8B7) and is predicted to regulate gene expression by modulating transcriptional elongation mediated by RNA polymerase II[3][5][8][10]. The protein is classified as a transcription factor due to its domain architecture and nuclear localization, but specific molecular functions and drug interactions remain uncharacterized. There are no current drugs known to target TCEANC, and it is not reported as a therapeutic target. Genetic alterations in TCEANC are associated with Simpson-Golabi-Behmel syndrome, type 2, but its broader disease associations and role in pathophysiology are unclear[3]. The gene is found in human (chromosome X), mouse, and other mammalian orthologs[4][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transcription elongation factor A N-terminal and central domain-containing protein (TCEANC).